Business Wire

INNIO Technology Selected for First 100% Hydrogen Engine Power Plant in Asia Pacific

19.11.2021 09:00:00 EET | Business Wire | Press release

Share

INNIO today announced that Hyosung Heavy Industries (Hyosung) has selected INNIO Jenbacher ‘Ready for Hydrogen’ engine technology for the first pilot power plant project in APAC that will be fueled by 100% hydrogen. The pilot hydrogen power plant will be built at the Hyosung Chemical Yongyeon Plant in Ulsan, South Korea, setting a benchmark by becoming the first 100% hydrogen power plant to be operated in the region. It will run on hydrogen produced as a byproduct at the chemical plant that is normally sold off to an industrial gas company. The project is expected to achieve commercial operation in 3Q 2022 and complete the demonstration by end of 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006247/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Park Jeong-Ha, General Manager at Hyosung (Photo: Business Wire)

“INNIO has based its strategy on hydrogen becoming a driver of the energy transition, as it is uniquely positioned to shape a low- through no-carbon energy sector. INNIO launched its ‘Ready for Hydrogen’ portfolio to meet customers’ demands for sustainable solutions, such as at Hyosung, to establish hydrogen-based power generation. We are pleased to be their hydrogen engine technology partner of choice and to establish the first 100% hydrogen power plant in APAC,” said Olaf Berlien, president and CEO of INNIO. “We will continue our relentless focus to deliver INNIO technologies and services that will help our customers to reduce their carbon footprint down to zero.”

“Hyosung is striving to improve its impact on climate change by embracing the global energy transition. We have joined forces with INNIO to support our efforts to reduce carbon emissions while exploring commercial and sustainable opportunities related with our hydrogen byproduct production,” commented Park Jeong-Ha, General Manager at Hyosung. “Our climate change response strategies have set the goal of reducing emissions and energy consumption while increasing energy efficiency. INNIO Jenbacher provides the efficient and proven technology that helps us meet this goal.”

As a shaper of a low-carbon economy, INNIO is preparing for a secure, affordable, and climate-neutral energy future for everyone. The pilot power plant using INNIO Jenbacher technology, will be the second power plant in the 1-MW range that can be fueled with 100% hydrogen. INNIO is a hydrogen pioneer for more than 20 years, when the first Jenbacher 150-kilowatt pilot engine ran on 100 percent hydrogen at a demonstration plant in northern Germany. Two decades later, in 2020, after a number of additional demonstration projects, INNIO and HanseWerk Natur demonstrated the world’s first hydrogen engine using variable hydrogen and natural gas mixtures up to 100% hydrogen on an INNIO Jenbacher engine. The collaboration with Hyosung now marks a further milestone for INNIO to help drive the energy transition.

About INNIO

INNIO is a leading provider of renewable gas and hydrogen-rich solutions and services for power generation and compression at or near the point of use. With our Jenbacher and Waukesha products, INNIO helps to provide communities, industry and the public access to sustainable, reliable and economical power ranging from 200 kW to 10 MW. We also provide life-cycle support and digital solutions to the more than 53,000 delivered gas engines globally, through our service network in more than 100 countries. We deliver innovative technology driven by sustainability, decentralization, and digitalization to help lead the way to a greener future. Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, U.S. For more information, visit the company's website at www.innio.com. Follow INNIO on Twitter and LinkedIn .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Susanne Reichelt
INNIO
+43 664 80833 2382
susanne.reichelt@innio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye